https://idataresearch.com/wp-content/uploads/2016/04/ReportIcon-Diabetes-MC.jpg

Insulin Market Analysis, Size, Trends | 2019-2025 | MedCore

  • Year: 2017
  • Scope: 2015-2025
  • Region: Europe, United States
  • Pages: 101
  • Published Date: 06/02/2019
  • Type: MedCore

Industry Trends

Patent expirations and the introduction of new products will lead to higher unit sales growth in the long-acting insulin segment, relative to the rapid-acting insulin, premixed insulin and human insulin segments. Combined with steady appreciation of ASP, it is projected that long-acting insulin will be the fastest growing segment in the total insulin market over the forecast period.

A patient is prescribed different types of insulin based on many factors discussed with their physician. This includes their response to insulin such as onset, peak and duration. Prescriptions also depend on the patient’s lifestyle including diet, alcohol and exercise, which influence insulin processing. Insulin choice may also be affected by willingness to give multiple doses and check blood sugar levels.

In both the U.S. and Europe insulin market, the largest segment is the long-acting insulin market. The long-acting insulin market has experienced increased competition, due to the expiration of product patents and the rise of biosimilar products. The second-largest segment in both regions is the rapid-acting insulin market. Increased adoption of insulin pump therapy will contribute to the growth of this market, as rapid-acting insulin is used for continuous subcutaneous insulin infusion (CSII).

Report Regional Coverage

Throughout this research series, iData has covered several countries in great detail. Each country may be purchased as a stand-alone report, tailoring the data to your needs. The covered countries are:

  • United States
  • Europe (15 countries including: Germany, France, U.K., Italy, Spain, Benelux (Belgium, Netherlands and Luxembourg), Scandinavia (Denmark, Finland, Norway and Sweden) Austria, Switzerland and Portugal)

 

 

The Only Medical Device Market Research With:

Unit Sales Growth Analysis
Average Selling Prices
Competitor Shares by Segment & Country
 SKU-Level Research Methods
 The Lowest Acquisition Cost

 

Highly Detailed Segmentation

  • Long-Acting Insulin Market
  • Ultra-Long-Acting Insulin Market
  • Rapid-Acting Insulin Market
  • Premixed Insulin Market
  • Human Insulin Market

 

Report Data Types Included

  • Unit Sales, Average Selling Prices, Market Value & Growth Trends
  • 10 Year Scope (3 Year Historical + 7 Year Forecast Period)
  • Market Drivers & Limiters for Each Segment
  • Competitive Analysis with Market Shares
  • Product Portfolios

Insulin Market Share Insights

In the U.S. and Europe, the leading competitor in the insulin market is Novo Nordisk. Novo Nordisk holds the leading position in the ultra-long-acting insulin and rapid-acting insulin markets and the second-leading position in the long-acting insulin, premixed insulin and human insulin markets. The company’s insulin product portfolio includes long-acting insulin analog, Levemir®, ultra-long-acting insulin analog, Tresiba®, ultralong-acting insulin analog and GLP-1 combo, Xultophy®, rapid-acting insulin analogs, NovoLog® and Fiasp®, premixed insulin analog, NovoMix® and human insulin, Novolin®.

Eli Lilly is the second-leading competitor in the U.S. insulin market. Eli Lilly holds the leading position in the premixed insulin and human insulin markets, the second-leading position in the rapid-acting insulin market and the third-leading position in the long-acting insulin market. The company’s product portfolio includes long-acting insulin analog biosimilar, Basaglar®, rapid-acting insulin analog, Humalog®, premixed insulin analog, Humalog® Mix and human insulin, Humulin®.

In the Europe market for insulin, Sanofi was the second-leading competitor. Sanofi holds the leading position in the long-acting insulin and ultra-long-acting markets and the third-leading position in the rapid-acting insulin and human insulin markets. The company’s insulin product portfolio includes long-acting insulin analog, Lantus®, long-acting insulin analog and glucagon-like-peptide 1 receptor agonist (GLP-1) combo, Soliqua®, ultra-long-acting insulin analog, Toujeo®, rapid-acting insulin analog, Apidra® and human insulin, Insuman®. The patent for Lantus® expired in 2015 has faced competition from Abasaglar®, a biosimilar product by Eli Lilly and Boehringer Ingelheim. In 2018, Sanofi launched Admelog®, a rapid-acting insulin analog biosimilar product to Humalog® by Eli Lilly.

 

About Our In-Depth MedCore Research

Our analysts meticulously research for up to 3 to 4 months to put together one suite of reports (MedSuite), which is a comprehensive analysis on a group of healthcare markets. A MedCore is one portion of that analysis that focuses on one market segment, and provides further detailed segmentation to get a much more granular set of market data.This MedCore is also found in the full report suite titled U.S. Market Report Suite for the Diabetes Market – MedSuite

Learn More about these product types







iData’s 9-Step Research Methodology

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology